Use of Colony-Stimulating Factors With Chemotherapy: Opportunities for Cost Savings and Improved Outcomes

Use of Colony-Stimulating Factors With Chemotherapy: Opportunities for Cost Savings and Improved Outcomes

Myeloid colony-stimulating factors (CSFs) decrease the risk of febrile neutropenia (FN) from high-risk chemotherapy regimens administered to patients at 20% or greater risk of FN, but little is known about their use in clinical practice. We evaluated CSF use in a multiregional population-based cohor...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JNCI : Journal of the National Cancer Institute 2011-06, Vol.103 (12), p.979-982
Hauptverfasser: Potosky, Arnold L., Malin, Jennifer L., Kim, Benjamin, Chrischilles, Elizabeth A., Makgoeng, Solomon B., Howlader, Nadia, Weeks, Jane C.
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Biological and medical sciences
Brief Communications
Chemotherapy
Clinical outcomes
Cohort Studies
Colony-Stimulating Factors - administration & dosage
Colony-Stimulating Factors - economics
Colorectal Neoplasms - drug therapy
Cost Savings
Drug Prescriptions - economics
Drug Prescriptions - statistics & numerical data
Evidence-Based Medicine
Female
Fever - etiology
Fever - prevention & control
Health care expenditures
Health Maintenance Organizations
HMOs
Humans
Lung Neoplasms - drug therapy
Male
Medical sciences
Middle Aged
Neutropenia - chemically induced
Neutropenia - complications
Neutropenia - prevention & control
Odds Ratio
Opportunity
Practice Guidelines as Topic
Risk Factors
Savings
Treatment Outcome
Tumors
United States
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Myeloid colony-stimulating factors (CSFs) decrease the risk of febrile neutropenia (FN) from high-risk chemotherapy regimens administered to patients at 20% or greater risk of FN, but little is known about their use in clinical practice. We evaluated CSF use in a multiregional population-based cohort of lung and colorectal cancer patients (N = 1849). Only 17% (95% confidence interval [CI] = 8% to 26%) patients treated with high-risk chemotherapy regimens received CSFs, compared with 18% (95% CI = 16% to 20%) and 10% (95% CI = 8% to 12%) of patients treated with intermediate- (10%-20% risk of FN) and low-risk (
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/djr152